ReviewBritish journal of clinical pharmacology2025
Appraising the visibility, relevance and impacts of clinical pharmacology.
Review in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Appraising the visibility, relevance and impacts of clinical pharmacology.British journal of clinical pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsClinical pharmacology (CP) used to be a strong medical and scientific field, but during the last three decades it seems to have lost some of its appeal. We reviewed the visibility, relevance and impact of CP and clinical pharmacologists across the globe and suggest ways to strengthen the discipline to address future pharmacotherapeutic challenges.
methodsLiterature consultations and multiple survey approaches through personal contacts with leading experts from high-income countries, Asia and Africa and with CP scientific journal editors with presentation, discussion and recommendations at a workshop (World Congress in Basic and Clinical Pharmacology, Glasgow 2023).
resultsHistorically, CP has been a leading discipline for the advancement of knowledge and practice of rational principles for human drug use. However, currently there is variable visibility and impact between countries in research, education and clinical services. The workshop participants agreed that CP continues to be an open transdisciplinary subject to address challenges of drug development with affordable access to essential medicines and rational use of new advanced therapies as well as essential medicines. Medical specialisation programmes in clinical pharmacology and therapeutics should be the norm and become attractive through introducing board programmes for accreditation of specialists building on models existing in some European countries, India, Nigeria and South Africa.
conclusionsClinical pharmacologists should collaborate across countries and disseminate success stories, demonstrating their essential contributions to medical science and patient care. A white book with comprehensive global representation on the future role, structure and impact of the discipline should be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.